EW — Edwards Lifesciences Corporation Common Stock

Why people talked about EW (2026-11-03)

• Edwards Lifesciences discussed CLASP II TR and PROGRESS trial results for tricuspid and TAVR treatments.
• The company highlighted PASCAL and TAVR data demonstrating patient benefits.
• A claim for the $39M Edwards deal must be submitted by Dec. 2, 2026, prior to the Dec. 16 approval hearing.